Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Issues Quarterly Earnings Results

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) posted its quarterly earnings results on Monday, August 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports.

Greenland Mines Ltd. Common Stock Price Performance

Shares of NASDAQ:GRML traded up $0.22 during trading on Thursday, hitting $5.26. The company had a trading volume of 1,569,064 shares, compared to its average volume of 136,493. Greenland Mines Ltd. Common Stock has a one year low of $4.37 and a one year high of $37.95. The stock has a market cap of $16.73 million, a price-to-earnings ratio of -16.44 and a beta of 7.13. The company has a fifty day simple moving average of $10.64 and a two-hundred day simple moving average of $17.51.

Insider Activity at Greenland Mines Ltd. Common Stock

In other Greenland Mines Ltd. Common Stock news, Director Jason David Sawyer bought 4,800 shares of the company’s stock in a transaction on Wednesday, July 22nd. The shares were bought at an average cost of $11.50 per share, for a total transaction of $55,200.00. Following the acquisition, the director directly owned 4,800 shares in the company, valued at approximately $55,200. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Riad Hussein El-Dada sold 3,500 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $11.50, for a total transaction of $40,250.00. Following the sale, the director directly owned 3,500 shares of the company’s stock, valued at $40,250. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Greenland Mines Ltd. Common Stock

A number of institutional investors have recently made changes to their positions in GRML. Geode Capital Management LLC lifted its holdings in Greenland Mines Ltd. Common Stock by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Greenland Mines Ltd. Common Stock during the fourth quarter worth about $126,000. Jane Street Group LLC purchased a new stake in Greenland Mines Ltd. Common Stock during the 4th quarter valued at about $64,000. Finally, XTX Topco Ltd grew its position in shares of Greenland Mines Ltd. Common Stock by 101.2% in the fourth quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after purchasing an additional 80,768 shares in the last quarter. 20.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen raised shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings upgraded shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Greenland Mines Ltd. Common Stock presently has an average rating of “Sell”.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.